Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.50 |
| ▸ | GLA | P06280 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | CASP7 | P55210 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747789 | 0.82 | CYP3A4 (0.48) | CYP3A4GLAMEN1KMT2AALDH1A1 | |
| SCHEMBL8884317 | 0.79 | CYP3A4 (0.46) | CYP3A4GLAMEN1KMT2AALDH1A1 | |
| SCHEMBL2573803 | 0.77 | CYP3A4 (0.56) | CYP3A4GLAMEN1KMT2AALDH1A1 | |
| SCHEMBL8886719 | 0.72 | CYP3A4 (0.50) | CYP3A4GLAMEN1KMT2AALDH1A1 | |
| SCHEMBL6907119 | 0.71 | RXRA (0.55) | CYP3A4GLAMEN1KMT2AALDH1A1 | |
| 4-Hydroxy-6-Methylpyran-2-One SCHEMBL320025 | 0.67 | — | — | |
| SCHEMBL8121427 | 0.67 | TYR (0.45) | CYP3A4GLAMEN1KMT2A | |
| SCHEMBL22149723 | 0.67 | MEN1 (0.44) | CYP3A4GLAMEN1KMT2AALDH1A1 | |
| SCHEMBL22149728 | 0.67 | CYP3A4 (0.44) | CYP3A4GLAMEN1KMT2AALDH1A1 | |
| SCHEMBL22149253 | 0.67 | MEN1 (0.44) | CYP3A4GLAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134696-B1 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS (SI) | 2017-05-17 | — | — | EP | disclosed |
| US-8471045-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-25 | — | — | US | disclosed |
| US-20120196333-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-8183397-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2012-05-22 | — | — | US | disclosed |
| US-20110178295-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-21 | — | — | US | disclosed |
| WO-2008119810-A2 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2008-10-09 | — | — | WO | disclosed |
| US-5670662-A | Pyranones | ZENECA LIMITED (GB) | 1997-09-23 | — | — | US | disclosed |
| US-5527916-A | Pyranones | ZENECA LIMITED (GB) | 1996-06-18 | — | — | US | disclosed |
| US-5443971-A | Pyranones | ZENECA LIMITED (GB) | 1995-08-22 | — | — | US | disclosed |
| EP-0604525-A1 | ENZYMATIC PRODUCTION OF OPTICAL ISOMERS OF TETRAHYDROPYRAN-2-ONES | ZENECA LIMITED (GB) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993006236-A1 | ENZYMATIC PRODUCTION OF OPTICAL ISOMERS OF TETRAHYDROPYRAN-2-ONES | ZENECA LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178295-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | CYP3A4 25/4885GLA 898/4885MEN1 2942/4885 |
| US-20120196333-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | CYP3A4 25/4885GLA 898/4885MEN1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.